FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045193617> ?p ?o ?g. }

• W2045193617 endingPage "740" @default.
• W2045193617 startingPage "732" @default.
• W2045193617 abstract "There is increasing interest in the use of a weekly administration of docetaxel as a way of reducing its hematologic toxicity. The purpose of the current randomized study was to evaluate the toxicity and efficacy of docetaxel plus cisplatin combination on 2 schedules in patients with previously untreated, advanced nonsmall-cell lung cancer (NSCLC).Consenting patients with advanced NSCLC were randomized to receive first-line chemotherapy with cisplatin 75 mg/m(2) on Day 1, plus 3-weekly (75 mg/m(2) on Day 1) or weekly (35 mg/m(2) on Days 1, 8, and 15 of a 4-week cycle) docetaxel, for up to 6 cycles.Of 86 patients accrued, 41 patients were treated with 3-weekly and 43 with weekly docetaxel plus cisplatin. The most frequent grade 3/4 toxicity in the 3-weekly arm was neutropenia (56% of patients). In those receiving the weekly regimen, the frequent grade 3/4 toxicities were fatigue (44%) and nausea/vomiting (35%). The overall response rate was 40% with the 3-weekly and 39% with the weekly arm (P = .74). The median progression-free survival was 4.3 months in the 3-weekly arm and 3.9 months in the weekly arm (P = .08) and the median survival was 10.3 and 10.0 months, respectively (P = .76). Quality of life data showed no relevant difference between the arms.The weekly schedule of docetaxel plus cisplatin combination as first-line chemotherapy for advanced NSCLC, while feasible, has no clear advantage over the standard 3-weekly regimen." @default.
• W2045193617 created "2016-06-24" @default.
• W2045193617 creator A5001297228 @default.
• W2045193617 creator A5013860466 @default.
• W2045193617 creator A5032367194 @default.
• W2045193617 creator A5044268319 @default.
• W2045193617 creator A5055097851 @default.
• W2045193617 creator A5057146015 @default.
• W2045193617 creator A5063736270 @default.
• W2045193617 creator A5073203839 @default.
• W2045193617 creator A5076190421 @default.
• W2045193617 creator A5078539188 @default.
• W2045193617 date "2007-01-01" @default.
• W2045193617 modified "2023-09-27" @default.
• W2045193617 title "Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer" @default.
• W2045193617 cites W1920828316 @default.
• W2045193617 cites W1969577451 @default.
• W2045193617 cites W1973155311 @default.
• W2045193617 cites W2036938290 @default.
• W2045193617 cites W2037139573 @default.
• W2045193617 cites W2053245757 @default.
• W2045193617 cites W2053432470 @default.
• W2045193617 cites W2054100499 @default.
• W2045193617 cites W2057346171 @default.
• W2045193617 cites W2094296847 @default.
• W2045193617 cites W2104255120 @default.
• W2045193617 cites W2109022672 @default.
• W2045193617 cites W2118281867 @default.
• W2045193617 cites W2127405377 @default.
• W2045193617 cites W2135222080 @default.
• W2045193617 cites W2139730244 @default.
• W2045193617 cites W2142809967 @default.
• W2045193617 cites W2145653040 @default.
• W2045193617 cites W2147075384 @default.
• W2045193617 cites W2155440695 @default.
• W2045193617 cites W2157784057 @default.
• W2045193617 cites W2158077876 @default.
• W2045193617 cites W2166399931 @default.
• W2045193617 cites W2167571044 @default.
• W2045193617 cites W2242204182 @default.
• W2045193617 cites W2269150820 @default.
• W2045193617 cites W4239714259 @default.
• W2045193617 doi "https://doi.org/10.1002/cncr.22446" @default.
• W2045193617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17211861" @default.
• W2045193617 hasPublicationYear "2007" @default.
• W2045193617 type Work @default.
• W2045193617 sameAs 2045193617 @default.
• W2045193617 citedByCount "23" @default.
• W2045193617 countsByYear W20451936172013 @default.
• W2045193617 countsByYear W20451936172014 @default.
• W2045193617 countsByYear W20451936172015 @default.
• W2045193617 countsByYear W20451936172017 @default.
• W2045193617 countsByYear W20451936172019 @default.
• W2045193617 countsByYear W20451936172020 @default.
• W2045193617 countsByYear W20451936172021 @default.
• W2045193617 crossrefType "journal-article" @default.
• W2045193617 hasAuthorship W2045193617A5001297228 @default.
• W2045193617 hasAuthorship W2045193617A5013860466 @default.
• W2045193617 hasAuthorship W2045193617A5032367194 @default.
• W2045193617 hasAuthorship W2045193617A5044268319 @default.
• W2045193617 hasAuthorship W2045193617A5055097851 @default.
• W2045193617 hasAuthorship W2045193617A5057146015 @default.
• W2045193617 hasAuthorship W2045193617A5063736270 @default.
• W2045193617 hasAuthorship W2045193617A5073203839 @default.
• W2045193617 hasAuthorship W2045193617A5076190421 @default.
• W2045193617 hasAuthorship W2045193617A5078539188 @default.
• W2045193617 hasConcept C126322002 @default.
• W2045193617 hasConcept C141071460 @default.
• W2045193617 hasConcept C143998085 @default.
• W2045193617 hasConcept C2776256026 @default.
• W2045193617 hasConcept C2776694085 @default.
• W2045193617 hasConcept C2777063308 @default.
• W2045193617 hasConcept C2778239845 @default.
• W2045193617 hasConcept C2778336483 @default.
• W2045193617 hasConcept C2778850193 @default.
• W2045193617 hasConcept C2780580376 @default.
• W2045193617 hasConcept C2781190966 @default.
• W2045193617 hasConcept C2781413609 @default.
• W2045193617 hasConcept C71924100 @default.
• W2045193617 hasConcept C90924648 @default.
• W2045193617 hasConceptScore W2045193617C126322002 @default.
• W2045193617 hasConceptScore W2045193617C141071460 @default.
• W2045193617 hasConceptScore W2045193617C143998085 @default.
• W2045193617 hasConceptScore W2045193617C2776256026 @default.
• W2045193617 hasConceptScore W2045193617C2776694085 @default.
• W2045193617 hasConceptScore W2045193617C2777063308 @default.
• W2045193617 hasConceptScore W2045193617C2778239845 @default.
• W2045193617 hasConceptScore W2045193617C2778336483 @default.
• W2045193617 hasConceptScore W2045193617C2778850193 @default.
• W2045193617 hasConceptScore W2045193617C2780580376 @default.
• W2045193617 hasConceptScore W2045193617C2781190966 @default.
• W2045193617 hasConceptScore W2045193617C2781413609 @default.
• W2045193617 hasConceptScore W2045193617C71924100 @default.
• W2045193617 hasConceptScore W2045193617C90924648 @default.
• W2045193617 hasIssue "4" @default.
• W2045193617 hasLocation W20451936171 @default.
• W2045193617 hasLocation W20451936172 @default.
• W2045193617 hasOpenAccess W2045193617 @default.

• next